by placing cooling blankets (model MTA-4702; Gaymar Industries, Inc., Orchard Park, NY) beneath the patients' bodies. All patients underwent tracheotomy and received ventilation (Aridyne 3600; Timeter Corp., St. Louis, MO). The patients in the hypothermia group received continuous infusions of a paralytic drug (Tracrium 10-40 mg/ hour) and choropromazine (5-10 mg/hour) administered using an infusion pump to prevent shivering. The dosage was given according to each patient's temperature, blood pressure, heart rate, and muscular tone. Once the patient's rectal temperature reached 33˚C (a mean of 15 hours after injury), it was kept at approximately that temperature (33-35˚C) 3 to 14 days, depending on the individual patient's ICP. When the patient's ICP returned to a normal level (ICP Ͻ 15 mm Hg), hypothermia was discontinued. The patients were passively rewarmed to a temperature of 37 to 38.3˚C at a rate no greater than 1˚C/hour, by gradual adjustment of the blanket thermostat. In the 44 patients assigned to the normothermia group, body temperature was maintained between 37˚C and 38˚C throughout the entire 14-day monitoring period.
The patients were treated according to guidelines for the management of severe TBI set forth by the Joint Section on Neurotrauma and Critical Care of the Brain Trauma Foundation and the American Association of Neurological Surgeons. 1 We rapidly evacuated large intracranial hematomas and hemorrhagic contusions. Each patient's cerebral perfusion pressure was maintained at a level higher than 70 mm Hg at all times by keeping mean arterial blood pressure between 90 and 120 mm Hg, and the ICP at a level below 25 mm Hg. A fiberoptic catheter was inserted to provide continuous measurement of ICP (model 3000; Camino Laboratories, San Diego, CA). Bolus intravenous infusions of mannitol (25-50 g every 6-8 hours) and flurosemide (20-40 mg every 6-8 hours) were administered to reduce intracranial hypertension. Corticosteroid medications were not used. The patient's temperature, respiratory rate, heart rate, blood pressure, cardiac rhythm, and oxygen saturation were continuously monitored (Hewlett Packard, Palo Alto, CA). Serum glucose, blood gases, and serum electrolytes were regularly measured.
Assessment of Neurological Outcome
A specialist in physical medicine and rehabilitation, who was unaware of the patients' treatment group assignments, determined neurological outcomes 1 year postinjury. The patients' neurological outcomes were scored according to the Glasgow Outcome Scale 13 as follows: 1, death; 2, vegetative state-unable to interact with the environment; 3, severe disability-unable to live independently, but able to follow commands; 4, moderate disability-capable of living independently, but unable to return to work or school; and 5, mild or no disability-able to return to work or school.
Statistical Analysis
Baseline characteristics, complications, ICP, blood glucose values, serum electrolyte levels, and outcomes in the two groups were compared using chi-square tests, Fisher's exact tests, or t-tests, as appropriate. A probability value less than 0.05 was considered significant. Results for groups are presented as the means Ϯ standard deviation.
Results
At 1 year post-TBI in the mild hypothermia group, the mortality rate was 25.58% (11 of 43 patients) and the rate of favorable outcome (good recovery or moderate disability) was 46.51% (20 of 43 patients). In the normothermia group, the mortality rate was 45.45% (20 of 44 patients) and the rate of favorable outcome was 27.27% (12 of 44 patients) (p Ͻ 0.05).
Within 24 hours after injury, the mean ICP was 29.63 Ϯ 2.25 mm Hg in the hypothermia group and 30.3 Ϯ 3 mm Hg in the normothermia group (p Ͼ 0.05). However, on the 7th day postinjury the mean ICP was 18.9 Ϯ 1.5 mm Hg in the hypothermia group and 28.13 Ϯ 2.25 mm Hg in the normothermia group (p Ͻ 0.01).
Within 72 hours after injury the mean serum glucose level was 10.2 Ϯ 2.4 mmol/L in the hypothermia group and 9.1 Ϯ 3.9 mmol/L in the normothermia group (p Ͼ 0.05). However, on the 7th day postinjury the mean serum glucose level was 5.6 Ϯ 1.4 mmol/L in the hypothermia group and 8.6 Table 2 provides details on serum levels of potassium, sodium, chloride, and calcium in the two groups. There was no difference between the two groups either before hypothermia was induced or after body temperature was normalized (p Ͼ 0.05).
At 1 year postinjury, the number of complications in these patients, including pneumonia, cardio-arrhythmia, hypotension, posttraumatic seizure, stress ulcer, diarrhea, and urinary infection, were not significantly different between the mild hypothermia and the normothermia groups (p Ͼ 0.05; Table 3 ).
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Protection provided by long-term mild hypothermia 547 19 compared the effects of moderate hypothermia and normothermia in 82 patients with severe closed-head injuries (GCS Score 3-7). At 12 months postinjury, 62% of patients in the hypothermia group and only 38% of those in the normothermia group had good outcomes. Shiozaki and colleagues 24 reported that mild hypothermia significantly increased survival rates (50% in the hypothermia group compared with 18% in the normothermia group) in patients with severe head injury (p Ͻ 0.05). Metz and associates 21 reported that moderate hypothermia therapy was applied to 10 patients with severe head injury, including seven patients with GCS Score 3, two with GCS Score 4, and one with GCS Score 6. Eight patients survived and seven had a good recovery.
There still is inconsistency in the duration of hypothermia prescribed for treatment of severe TBI in different trauma centers. Some head-trauma centers insist that the length of hypothermia therapy should be shorter than 48 hours to prevent complications resulting from long-term hypothermia. 7, 19, 21 Other centers recommend that hypothermia be maintained until ICP returns to the normal range, which usually occurs within 3 to 14 days postinjury. 16, 24 Traumatic brain edema and high ICP usually last more than 7 days in patients with severe TBI, especially in those who have massive cerebral contusion and brain hernia. The difference in duration of hypothermia may be the reason for differences in outcomes in patients treated with hypothermia in different trauma centers. Therefore, we suggest that mild-to-moderate hypothermia should be maintained until the patient's ICP returns to the normal range as long as complications, such as pneumonia or other systemic infections, do not develop.
Our data showed that pathological findings on CT scans do not affect the protective effects provided by long-term mild hypothermia in patients with severe TBI. Patients with TBI who had GCS scores of 8 or lower randomly entered our clinical trial regardless of whether there was evidence of intracranial hematoma, cerebral contusion, or tSAH on the initial CT scan obtained after admission. Actually, we used CT findings as well as continuous ICP monitoring to help us determine the duration of mild hypothermia to be used in individual patients. If results of CT scanning demonstrated narrowing or disappearance of the patient's basal cisterns and ventricular systems or evidence of massive brain edema and cerebral contusion, we usually prescribed a relatively longer period of mild hypothermia. Conversely, if results of CT scanning demonstrated normal-sized basal cisterns and ventricular systems or mild brain edema and cerebral contusion, we prescribed a relatively shorter period of mild hypothermia therapy. The mechanisms of hypothermic protection observed after brain injury have not been elucidated. However, recent experimental studies have demonstrated a number of possible mechanisms. Mild hypothermia: 1) reduces cerebral glucose metabolism and cerebral oxygen metabolism and decreases cerebral lactate content following brain injury; 12, 18, 28 2) prevents disruption of the blood-brain barrier after ischemia or TBI and reduces brain edema following TBI; 15, 20, 25 3) diminishes levels of endogenous toxic neurotransmitters, including glutamate, glycine, aspartate, acetylcholine, and norepinephrine, into the brain after TBI; 3,23 4) inhibits excessive calcium entry into neurons and intracellular calcium overload following brain injury; 22 5) protects membrane structural proteins in neurons, such as microtubule-associated protein-2, after TBI; 26 and 6) may prevent diffuse axonal injury following TBI. 20 Systemic cooling was induced using a cooling blanket and the patients were given a muscle relaxant and controlled or assisted ventilation to prevent shivering. Patients remained in a state of mild hypothermia for 3 to 14 days without exhibiting significant side effects or complications. We believe that systemic mild hypothermia induced and maintained using a cooling blanket with administration of a muscle relaxant is a safe and effective measure for management of severe TBI. However, when neurosurgeons decide to treat a patient with mild hypothermia, the following concerns should be borne in mind.
1) The combination of mild hypothermia and muscle relaxant therapy may inhibit the cough reflex, which may increase the possibility of respiratory infections. 7 To de- crease the occurrence of pneumonia in our study, all patients with severe TBI received a tracheotomy instead of tracheal intubation as soon as possible after hospital admission, because long-term tracheal intubation may easily cause respiratory obstruction of blood, sputum, and gastric contents, possibly resulting in pneumonia. Nurses were instructed to turn the patient over and slap the back of the chest as well as to perform tracheal suction every 15 minutes to keep the respiratory tract clean. Sputum bacteria cultures and antibody sensitivity tests were performed every 2 days to assist the physician in finding the most sensitive antibody. Tracheoscopy was used to clean out sputum and secretions of the trachea and to administer intratracheal medication.
2) The dosage and speed of action of the muscle relaxant must be controlled by an infusion pump, depending on the patient's physiological condition including temperature, blood pressure, heart rate, and muscle tone. The purpose and favorable dosage of a muscle relaxant was only designed to prevent shivering during hypothermia; the coughing reflex must continue to exist. 3) Patients with cardiovascular diseases or traumatic shock, and patients younger than 15 years or older than 65 years of age should not receive hypothermia therapy.
